Literature DB >> 32512607

Quality Improvement Efforts Reduce Incidence of Surgical Necrotizing Enterocolitis and Related Deaths.

Gillian R Goddard1, Kera McNelis2,3, Anne Poindexter1,2, Todd Jenkins1,2, Jacqueline Wessel1, Amy T Nathan2,3, Michael A Helmrath1,2, Brenda Poindexter2,3.   

Abstract

OBJECTIVE: The aim of this study was to determine whether a regional quality improvement (QI) initiative decreased incidence and severity of surgical necrotizing enterocolitis (NEC) in very low birth weight (VLBW) infants. STUDY
DESIGN: A retrospective review of all VLBW infants who received care at one of the three hospitals involved in a NEC QI initiative from 2011 to 2016. Primary outcome was the number of surgical NEC cases per year. Secondary outcomes included associated outcomes and mortality.
RESULTS: Sixty-three infants with either a diagnosis of Stage III NEC (n = 40) or spontaneous intestinal perforation (SIP) (n = 23) were included. The incidence of medical and surgical NEC and the mortality rate of infants with surgical NEC decreased over time. Incidence and mortality of SIP did not significantly change.
CONCLUSION: A regional QI bundle to reduce the overall incidence of NEC also significantly decreased the incidence of surgical NEC and all-cause mortality of infants diagnosed with surgical NEC. KEY POINTS: · QI reduces surgical necrotizing enterocolitis.. · Reduction in NEC rate improves mortality.. · Human milk does not change SIP incidence.. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32512607     DOI: 10.1055/s-0040-1712967

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  1 in total

1.  Delay in achieving enteral autonomy and growth outcomes in very low birth weight infants with surgical necrotizing enterocolitis.

Authors:  Kera McNelis; Gillian Goddard; Todd Jenkins; Anne Poindexter; Jacqueline Wessel; Michael Helmrath; Brenda Poindexter
Journal:  J Perinatol       Date:  2020-12-02       Impact factor: 3.225

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.